Skip to main navigation Skip to search Skip to main content

Interaction between accumulated 21-deoxysteroids and mineralocorticoid signaling in 21-hydroxylase deficiency

  • Simon Travers
  • , Claire Bouvattier
  • , Jérôme Fagart
  • , Laetitia Martinerie
  • , Say Viengchareun
  • , Eric Pussard
  • , Marc Lombès
  • INSERM U869
  • Université Paris-Saclay
  • Assistance Publique-Hôpitaux de Paris
  • Centre de Référence des Maladies Rares du Développement Génital (DEVGEN)
  • Assistance Publique Hôpitaux de Paris
  • Paris Descartes University

Research output: Contribution to journalArticlepeer-review

Abstract

21-Hydroxylase deficiency (21OHD) is a rare genetic disorder in which salt-wasting syndrome occurs in 75% of cases, due to inability to synthesize cortisol and aldosterone. Recent mass spectrometry progress allowed identification of 21-deoxysteroids, i.e., 17-hydroxyprogester-one (17OHP), 21-deoxycortisol (21DF), and 21-deoxycorticosterone (21DB). We hypothesized that they may interfere with mineralocorticoid signaling and fludrocortisone therapy in patients with congenital adrenal hyperplasia (CAH) without effective glucocorticoid replacement and ACTH suppression. Our goal was to quantify circulating 21-deoxysteroids in a pediatric cohort with CAH related to 21OHD and to examine their impact on mineralocorticoid receptor (MR) activation. Twenty-nine patients with salt-wasting phenotype were classified in two groups according to their therapeutic control. During routine follow-up, 17OHP, 21DF, 21DB, and cortisol levels were quantified by liquid chromatography with tandem mass spectrometry before hydrocortisone intake and 1 and 2.5 h following treatment administration. Luciferase reporter gene assays were performed on transfected HEK293T cells while in silico modeling examined structural interactions between these steroids within ligand-binding domain of MR. Plasma 17OHP, 21DF, and 21DB accumulate in uncontrolled patients reaching micromolar concentrations even after hydrocortisone intake. 21DF and 21DB act as partial MR agonists with antagonist features similar to 17OHP, consistent with altered anchoring to Asn770 and unfavorable contact with Ala773 in ligand-binding pocket of MR. Our results demonstrate a complex interaction between all accumulating 21-deoxysteroids in uncontrolled 21OHD patients and mineralocorticoid signaling and suggest that appropriate steroid profiling should optimize management and follow-up of such patients, as keeping those steroids to low plasma levels should attest therapeutic efficacy and prevent interference with MR signaling.

Original languageEnglish
Pages (from-to)E102-E110
JournalAmerican Journal of Physiology - Endocrinology and Metabolism
Volume318
Issue number2
DOIs
Publication statusPublished - 1 Feb 2020
Externally publishedYes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • 17-hydroxyprogesterone
  • 21-deoxycorti-sol
  • 21-deoxycorticosterone
  • Congenital adrenal hyperplasia
  • LC-MS/MS
  • Mineralocorticoid receptor

Fingerprint

Dive into the research topics of 'Interaction between accumulated 21-deoxysteroids and mineralocorticoid signaling in 21-hydroxylase deficiency'. Together they form a unique fingerprint.

Cite this